Kite announces updated data from ZUMA-3 study of KTE-X19 in adult patients with relapsed or refractory ALL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kite, a Gilead company, announced updated results from ZUMA-3, a single-arm phase I/II study evaluating KTE-X19 (formerly KTE-C19), an investigational CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed or refractory acute lymphoblastic leukemia.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login